CNBC's Wilfred Frost reports that Wells Fargo's board is considering executive clawbacks following the recent fraudulent accounts scandal, according to Dow Jones.
Mary Uhl-Bien, Neeley School of Business, comments on two high-profile hearings this week in Congress; Wells Fargo CEO John Stumpf about the banks account scandal, and Mylan CEO Heather Bresch on the huge price hike in EpiPens.
CEOs aren't alone bringing home giant paychecks from the nation's big banks.
Bill George, Harvard Business School Senior Fellow and Former Medtronic Chairman, weighs in on Mylan CEO Heather Bresch's upcoming testimony on Capitol Hill over the EpiPen pricing debate.
Mike Mayo, CLSA bank analyst, says John Stumpf's prepared testimony doesn't answer a lot of questions. Also Mayo explains why he supports clawbacks and accountability from top leadership at the bank.
The U.S. is seeing a populist revolt, says Walter Isaacson, Aspen Institute, discussing the link between executive compensation structures and anger in America, as Wells Fargo CEO John Stump and Mylan CEO Heather Bresch head to Capitol Hill to testify.
Scott Gottlieb AEI resident fellow, and Sam Waksal, Kadmon Corporation, discuss whether regulations will impede innovation in the pharmaceutical industry.
Scott Gottlieb, AEI resident fellow, and Sam Waksal, Kadmon Corporation, discuss how competition impacts drug pricing and whether the FDA is working fast enough to streamline its approval process.
Scott Gottlieb, AEI resident fellow, and Sam Waksal, Kadmon Corporation, discuss the controversy surround the price hikes of Mylan's EpiPen and the problems that arise when companies obtain monopolies on certain drugs.
CNBC's Meg Tirrell follows the economics of the U.S. pharmaceutical supply chain.
CNBC's Meg Tirrell breaks down the cost of Mylan's EpiPen.
CNBC's Meg Tirrell reports Mylan Pharmaceuticals is under fire for raising the price of EpiPens more than 400-percent since 2007.
The "Squawk Box" news team discusses some of the morning's most provocative headlines, including the price hike in EpiPens as compensation for top executives at Mylan soar.
One of the U.K.’s best-known fund managers has scrapped bonuses at his investment management firm, saying there is little correlation between bonuses and performance.
James Dix, Wedbush Securities media analyst, shares his take on Viacom, following the news of the expected $72 million severance package for CEO Philippe Dauman.
Eric Jackson, Spring Owl Asset Management, discusses the corporate governance issues surrounding Viacom and CEO Philippe Dauman's reported $72 million severance package, with the "FMHR" traders and Rob Sechan, UBS Private Wealth Management.
The "FMHR" traders and Rob Sechan, UBS Private Wealth Management, discuss the trade on Viacom following the news of the expected $72 million severance package for CEO Philippe Dauman.
CNBC's Julia Boorstin reports the latest on the expected severance pay for CEO Philippe Dauman to step down from Viacom.
Kara Swisher, Recode executive editor, discusses the latest on Viacom with Philippe Dauman reportedly getting a large compensation package to exit his role as CEO.
It's getting tougher to be a CEO — if you don't work for one of the giant banks.